Last reviewed · How we verify
sub cutaneous liraglutide
Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying.
Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying. Used for Type 2 diabetes mellitus, Weight management in obese or overweight patients.
At a glance
| Generic name | sub cutaneous liraglutide |
|---|---|
| Also known as | Victoza |
| Sponsor | Yaounde Central Hospital |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Liraglutide binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion. It also reduces glucagon secretion when blood glucose is elevated and delays gastric emptying, leading to reduced postprandial glucose excursions. These combined effects improve glycemic control in type 2 diabetes and promote modest weight loss.
Approved indications
- Type 2 diabetes mellitus
- Weight management in obese or overweight patients
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Headache
- Hypoglycemia (when combined with insulin or sulfonylureas)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sub cutaneous liraglutide CI brief — competitive landscape report
- sub cutaneous liraglutide updates RSS · CI watch RSS
- Yaounde Central Hospital portfolio CI